Longeveron reports Q3 2022 net loss of $5.2M; completes Phase 2a Alzheimer's enrollment

Longeveron Inc.

2022-Q3 EPS reported -$0.69 revenue$1,101,000

Net loss of $5.2M ($0.25 per share) vs $4.9M in Q3 2021; revenue up to $0.3M from $0.2M.
Completed enrollment in Phase 2a Lomecel-B trial for mild Alzheimer's Disease; topline results expected 2024.
FDA granted Fast Track Designation for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS).
Cash and short-term investments of $22.3M; expected runway into first half 2024.
R&D expenses increased 45% to $2.9M; G&A decreased 31% to $2.1M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Longeveron Inc. reported third quarter ended September 30, 2022 results: revenue $0.3 million.

Period: third quarter ended September 30, 2022
Revenue: $0.3 million
Result: reported results

Exact text from the filing

Revenue for the third quarters of 2022 and 2021 was $0.3 million and $0.2 million, respectively.

View on SEC.gov

Browse all earnings releases →

Longeveron Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-071704

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.